Matching articles for "finerenone"
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • May 26, 2025; (Issue 1729)
Pharmacologic management of chronic heart failure
(HF) is primarily determined by the patient's left
ventricular ejection fraction (LVEF) and severity of
symptoms. Patients with chronic HF who have an
LVEF...
Pharmacologic management of chronic heart failure
(HF) is primarily determined by the patient's left
ventricular ejection fraction (LVEF) and severity of
symptoms. Patients with chronic HF who have an
LVEF ≤40% are considered to have heart failure with
reduced ejection fraction (HFrEF) and those with an
LVEF ≥50% are considered to have heart failure with
preserved ejection fraction (HFpEF). Patients with an
LVEF of 41-49% have heart failure with mildly reduced
or mid-range ejection fraction.
Comparison Chart: Some Drugs for HFrEF
The Medical Letter on Drugs and Therapeutics • May 26, 2025; (Issue 1729)
...
View the Comparison Chart: Some Drugs for HFrEF
In Brief: Finerenone (Kerendia) for Diabetic Kidney Disease
The Medical Letter on Drugs and Therapeutics • January 23, 2023; (Issue 1668)
Recently published guidelines from the American
Diabetes Association (ADA) and the Kidney Disease:
Improving Global Outcomes (KDIGO) Diabetes Work
Group recommend addition of the oral...
Recently published guidelines from the American
Diabetes Association (ADA) and the Kidney Disease:
Improving Global Outcomes (KDIGO) Diabetes Work
Group recommend addition of the oral nonsteroidal
mineralocorticoid receptor antagonist (MRA)
finerenone (Kerendia) to standard treatment in
patients with type 2 diabetes and chronic kidney
disease (CKD).
Finerenone (Kerendia) for Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • August 23, 2021; (Issue 1631)
Finerenone (Kerendia – Bayer), an oral nonsteroidal
mineralocorticoid receptor antagonist (MRA), has
been approved by the FDA to reduce the risk of
sustained eGFR decline, end-stage renal...
Finerenone (Kerendia – Bayer), an oral nonsteroidal
mineralocorticoid receptor antagonist (MRA), has
been approved by the FDA to reduce the risk of
sustained eGFR decline, end-stage renal disease,
nonfatal MI, hospitalization for heart failure (HF), and
cardiovascular death in adults with chronic kidney
disease (CKD) associated with type 2 diabetes. It is the
first nonsteroidal MRA to be approved in the US.